Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Oestrogen receptor low positive breast cancer: associations with prognosis
ConclusionWomen with ER Low Positive tumours diagnosed in a time period when adjuvant therapy was available had tumours of smaller size, lower grade, and lower proliferative status, and similar prognosis to those with ER  ≥ 10% compared to women diagnosed earlier. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy
This study shows that the cumulative incidence of distant metastasis is much lower than other cause mortality in older women with breast cancer treated with PET, especially in the presence of geriatric characteristics or comorbidities. This confirms the importance of assessment of geriatric characteristics to aid counseling of older women. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
ConclusionAfter adjustment of cfDNA level,PIK3CA andTP53 mutations observed in liquid biopsy exerted detrimental effects on the outcome of ET-based regimens. The AF ofPIK3CA orTP53 may be a surrogate marker for PFS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients
ConclusionsOur study suggests that circulating APOM is significantly linked with reduced mortality in metastatic breast cancer patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Sexual health in long-term breast cancer survivors: a comparison with female population controls from the HUNT study
ConclusionSexual health impairments are more common in BCSs 8 years after diagnosis compared to similar aged population controls. During follow-up, attention to such impairments, especially among women diagnosed at premenopausal age and treated with heavy systemic treatment, is warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
ConclusionShort-term NET frequently and preferentially upregulates HER2 over other HER family RTKs in early-stage HR+/HER2- BC and may be a promising strategy to identify tumors that utilize HER2 as an early endocrine escape pathway.Clinical trial registryTrial registration number: NCT03219476. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system
ConclusionLongitudinal screening adherence in individuals with PVs in breast cancer associated genes, as measured by the proportion of time covered, is low; adherence to annual breast MRI falls below that of annual mammography. Additional research should examine screening behavior in individuals with PVs in breast cancer associated genes with a goal of developing interventions to improve adherence to recommended risk management. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC –MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement
ConclusionsLetrozole supresses E2 and E1 completely below the LLOQ of the LC –MS/MS in postmenopausal women. High pre-treatment E2 levels were associated with more joint and muscle pain during letrozole. Automated immunoassays are unsuitable for E2 monitoring during letrozole therapy due to poor sensitivity. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 27, 2023 Category: Cancer & Oncology Source Type: research

Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact
ConclusionsHigh-grade DCIS exhibits all the molecular subtypes previously identified in IBC, but with a somewhat different distribution in our cohort. HER2-enriched subtype is substantially related to the presence of an invasive component in DCIS; consequently, it is regarded as a high-risk entity. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
ConclusionsThis data points out the need for new therapies for those patients. A longer follow-up of the monarchE study to see the real final benefit with abemaciclib is warranted.Trial registrationClinTrials.gov: GEICAM/9906: NCT00129922; GEICAM/ 2003-10: NCT00129935 and GEICAM/ 2006-10: NCT00543127. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
ConclusionThe results suggest that administering trilaciclib prior to GCb may modulate the composition and response of immune cell subsets to TNBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
ConclusionSubstantial heterogeneity in the use of NST with HR+/HER2-breast cancer exists in Europe. While stringent guidelines are available for its use in triple-negative and HER2+  breast cancer, there is a need for the development of and adherence to well-defined recommendations for HR+/HER2-breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

Preventative therapy for breast cancer: a clinical experience
ConclusionsWomen at increased risk of breast cancer accept additional screening but are reluctant to take preventative therapy. This suggests that stratified screening methods using risk calculations would have high uptake. Raising awareness of preventative therapy is important and the breast cancer community has yet to find the optimum timing and formula for discussing it and must accept women ’s informed preferences above artificial targets.Registration numbersThe PIONEER study was granted Health Research Authority (HRA) ethical approval by the Westminster Ethics Committee. IRAS project ID 265619, ClinicalTrials.gov Id...
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer
ConclusionAfter adjustment for demographic, clinicopathological, and socioeconomic factors; NHB women with IBC had similar odds of receiving surgery, chemotherapy, and radiation therapy, but were more likely to die of the disease compared to their NHW counterparts. Our findings suggest the presence of masked tumor biology, treatment, or socioeconomic factors associated with race that can lead to worse IBC outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research

HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity
ConclusionHSD17B4 KO in BT-474 cells caused a decrease of PUFAs, increased Akt phosphorylation, enhanced glucose dependence of OxPhos, and increased sensitivity to inhibition of HER2, upstream of Akt. This mechanism may be applicable to other HER2-positive glucose-dependent breast cancer cells withHSD17B4 silencing. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 22, 2023 Category: Cancer & Oncology Source Type: research